[4P-0549(1PW-13-8)] Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

Kenichi Iwai^1,2,7, Tadahiro Nambu¹, Ryo Dairiki¹, Momoko Ohori¹, JIe Yu², Krissy Burke², Masamitsu Gotou³, Yukiko Yamamoto¹, Shunsuke Ebara¹, Sachio Shibata¹, Ryosuke Hibino¹, Satoru Nishizawa¹, Tohru Miyazaki¹, Misaki Homma¹, Yuya Oguro¹, Takashi Imada¹, Nobuo Cho¹, Noriko Uchiyama⁴, Akifumi Kogame⁵, Toshiyuki Takeuchi⁵, Osamu Kurasawa¹, Kazunori Yamanaka³, Huifeng Niu⁶, 〇Akihiro Ohashi^1,2,7 (1.Onc. DDU, Takeda Pharmaceutical Company Limited, 2.Onc. DDU, Takeda Pharmaceuticals International Co., 3.InteRL Lab., Takeda Pharmaceutical Company Limited, 4.Biomol. Res. Lab., Takeda Pharmaceutical Company Limited, 5.DMPK Res. Lab., Takeda Pharmaceutical Company Limited, 6.Translational & Biomarker Res., Takeda Pharmaceuticals International Co., 7.Div. Translational Genomics, EPOC, National Cancer Center)

CDC7 inhibitor, TAK-931, replication stress, cancer therapeutic drug, predictive biomarker